Mouse models of high-risk neuroblastoma

被引:0
作者
Alvin Kamili
Caroline Atkinson
Toby N. Trahair
Jamie I. Fletcher
机构
[1] UNSW Sydney,Children’s Cancer Institute Australia, Lowy Cancer Research Centre
[2] UNSW Sydney,School of Women’s and Children’s Health
[3] Sydney Children’s Hospital,Kids Cancer Centre
来源
Cancer and Metastasis Reviews | 2020年 / 39卷
关键词
Neuroblastoma; GEMM; PDX; Mouse model; Pre-clinical testing;
D O I
暂无
中图分类号
学科分类号
摘要
Informative and realistic mouse models of high-risk neuroblastoma are central to understanding mechanisms of tumour initiation, progression, and metastasis. They also play vital roles in validating tumour drivers and drug targets, as platforms for assessment of new therapies and in the generation of drug sensitivity data that can inform treatment decisions for individual patients. This review will describe genetically engineered mouse models of specific subsets of high-risk neuroblastoma, the development of patient-derived xenograft models that more broadly represent the diversity and heterogeneity of the disease, and models of primary and metastatic disease. We discuss the research applications, advantages, and limitations of each model type, the importance of model repositories and data standards for supporting reproducible, high-quality research, and potential future directions for neuroblastoma mouse models.
引用
收藏
页码:261 / 274
页数:13
相关论文
共 50 条
  • [21] Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma
    Szychot, Elwira
    Peregud-Pogorzelski, Jaroslaw
    Wawrykow, Pawel
    Brodkiewicz, Andrzej
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2016, 70 : 1001 - 1004
  • [22] MELK is a novel therapeutic target in high-risk neuroblastoma
    Guan, Shan
    Lu, Jiaxiong
    Zhao, Yanling
    Yu, Yang
    Li, Hui
    Chen, Zhenghu
    Shi, Zhongcheng
    Liang, Haoqian
    Wang, Mopei
    Guo, Kevin
    Chen, Xiangmei
    Sun, Wenjing
    Bieerkehazhi, Shayahati
    Xu, Xin
    Sun, Surong
    Agarwal, Saurabh
    Yang, Jianhua
    ONCOTARGET, 2018, 9 (02) : 2591 - 2602
  • [23] The efficacy of delayed surgery in children with high-risk neuroblastoma
    Ali, Varan
    Vural, Kesik
    Emin, Senocak Mehmet
    Gulsev, Kale
    Canan, Akyuz
    Munevver, Buyukpamukcu
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 268 - 271
  • [24] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [25] New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma
    Wagner, Lars M.
    Danks, Mary K.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 107 (01) : 46 - 57
  • [26] Retrospective analysis of relapsed abdominal high-risk neuroblastoma
    Duebbers, Martin
    Simon, Thorsten
    Berthold, Frank
    Fischer, Janina
    Volland, Ruth
    Hero, Barbara
    Cernaianu, Grigore
    JOURNAL OF PEDIATRIC SURGERY, 2018, 53 (03) : 558 - 566
  • [27] Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
    Tran, Hung C.
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima F.
    Mascarenhas, Leo
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (01) : 26 - 31
  • [28] Ultrahigh-risk Group Within the High-risk Neuroblastoma Category
    Saarinen-Pihkala, Ulla M.
    Jahnukainen, Kirsi
    Wikstrom, Sakari
    Koivusalo, Antti
    Karikoski, Riitta
    Sariola, Hannu
    Hovi, Liisa
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2013, 35 (06) : E254 - E259
  • [29] A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma
    Moreno, Lucas
    Dubois, Steven G.
    Bird, Nicholas
    Knox, Leona
    Ludwinski, Donna
    Pearson, Andrew D. J.
    Beck-Popovic, Maja
    Bagatell, Rochelle
    PEDIATRIC BLOOD & CANCER, 2025,
  • [30] Bronchiectasis following treatment for high-risk neuroblastoma: A case series
    Adams, Madeleine
    Traunecker, Heidi
    Doull, Iolo
    Cox, Rachel
    PEDIATRIC BLOOD & CANCER, 2017, 64 (10)